Breast Elasticity Imaging During Neoadjuvant Chemotherapy
Recruiting · NCT04824027 · Interventional (participants receive a specific treatment) · Lead sponsor: Columbia University
View the official record on ClinicalTrials.gov →Interventions studied
Harmonic motion imaging
What this trial is about
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Women age ≥18
- Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treating physician.
- Any stage invasive breast cancer provided the primary breast tumor size is ≥ 4 mm
Exclusion criteria
- Patient is pregnant or lactating
- Presence of breast implants
- History of laser or radiation therapy to the affected breast
Where it is running
1 location listed across 1 US state.
- Columbia University Irving Medical Center/NYP - New York, New York, United States